About Gossamer Bio, Inc.
https://www.gossamerbio.comGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States.
CEO
Faheem Hasnain
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 87
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:18.09M
Value:$46.14M
OCTAGON CAPITAL ADVISORS LP
Shares:17.05M
Value:$43.48M
BLACKROCK, INC.
Shares:13.85M
Value:$35.31M
Summary
Showing Top 3 of 185
About Gossamer Bio, Inc.
https://www.gossamerbio.comGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $13.29M ▲ | $62.41M ▲ | $-48.22M ▼ | -362.73% ▼ | $-0.21 ▼ | $-45.47M ▼ |
| Q2-2025 | $11.49M ▲ | $50.25M ▲ | $-38.27M ▼ | -333.13% ▲ | $-0.17 ▼ | $-35.32M ▼ |
| Q1-2025 | $9.89M ▲ | $46.7M ▲ | $-36.64M ▼ | -370.49% ▼ | $-0.16 ▼ | $-33.55M ▼ |
| Q4-2024 | $9.38M ▼ | $45.51M ▲ | $-33.03M ▼ | -352.16% ▼ | $-0.15 ▼ | $-31.63M ▼ |
| Q3-2024 | $9.48M | $43.4M | $-30.8M | -324.93% | $-0.14 | $-28.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $180.22M ▼ | $208.82M ▼ | $291.15M ▲ | $-82.33M ▼ |
| Q2-2025 | $212.92M ▼ | $240.93M ▼ | $287.03M ▲ | $-46.11M ▼ |
| Q1-2025 | $257.93M ▼ | $280.59M ▼ | $286.84M ▲ | $-6.25M ▼ |
| Q4-2024 | $294.52M ▼ | $315.29M ▼ | $285.8M ▼ | $29.49M ▼ |
| Q3-2024 | $327.03M | $350.88M | $296.74M | $54.14M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-48.22M ▼ | $-36.17M ▲ | $17.01M ▼ | $1.87M ▲ | $-17.38M ▼ | $-36.17M ▲ |
| Q2-2025 | $-38.27M ▼ | $-47.06M ▼ | $44.13M ▲ | $94K ▼ | $-2.71M ▲ | $-47.11M ▼ |
| Q1-2025 | $-36.64M ▼ | $-39.72M ▼ | $22.06M ▼ | $504K ▲ | $-17.05M ▼ | $-39.75M ▼ |
| Q4-2024 | $-33.03M ▼ | $-35.48M ▼ | $53.22M ▲ | $0 ▼ | $17.61M ▲ | $-35.48M ▼ |
| Q3-2024 | $-30.8M | $-32.03M | $-26.75M | $281K | $-58.41M | $0 |
Revenue by Products
| Product | Q2-2024 | Q3-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License and Service | $90.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Faheem Hasnain
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 87
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:18.09M
Value:$46.14M
OCTAGON CAPITAL ADVISORS LP
Shares:17.05M
Value:$43.48M
BLACKROCK, INC.
Shares:13.85M
Value:$35.31M
Summary
Showing Top 3 of 185